World Cancer Day will, we hope, set the stage for more meaningful work on cancer control on a global scale. As Goodwill Ambassador for Cancer Control for the World Health Organization, and as a breast cancer survivor and 30-year advocate to end breast cancer, I know too well the pain and devastation of this disease. I’ve seen it in my own family, in my sister who died of breast cancer 30 years ago. And I’ve seen it all too painfully in the faces of members of our global family — women dying in undeveloped countries of cancers that might have been easily treated in the West.
Cancer is the leading cause of death around the world, killing more people every year than AIDS, malaria and tuberculosis combined. The World Health Organization estimates that, without appropriate intervention, 84 million people will die from cancer between 2005 and 2015. While the emotional impact of losing a loved one to cancer is immeasurable, the economic impact of premature death caused by cancer is measurable, and it is devastating. A recent study found that 25 nations are losing more than 2 percent of their GDP to deaths and disability caused by cancer. These figures are only for the deaths that can be attributed directly to cancer. Many deaths each year go unreported, because many countries lack cancer registries.
This may be because at one time, cancer was considered a “western” or “rich person’s disease”– I’ve actually been told that in my travels. Now, it is making its way into developing countries and evolving into a global crisis. Reliable public health numbers help explain why cancer cases are growing in the developing world. For one thing, the use of tobacco, unhealthy diet, and other cancer risks are making their way into low- and middle-income countries. And a rise in cancer is also a natural consequence of people living longer due to decreased mortality from infectious diseases. Our very success against those afflictions has extended more lives into the cancer demographic – those middle and later years when cancer is more likely to occur.
Cancer therefore burdens rich and poor countries alike. It is the great equalizer, affecting men, women, young, old, of every nationality and political stripe. Without comprehensive cancer control plans, the developing world is facing a disease tsunami that will overload healthcare systems, strain national budgets, destroy local economies, and devastate families. By 2020, an estimated 60 percent of all new cancer cases will occur in the least developed nations. Amazingly, however, only 5 percent of global resources for cancer are spent there.
I regularly explain the importance of including cancer in the global health agenda, mindful of the argument that with so many pressing programs competing for limited resources, fighting cancer is too complicated or too expensive, especially for low-resource countries. Unhappily, the world does not have a choice. The cancer burden will continue to grow, and with it the economic impact of the disease, estimated at $895 billion in 2008.
My organization, Susan G. Komen for the Cure, is all too familiar with the need to develop and implement global cancer programs. We’ve been involved in international programs for more than a decade and today have breast cancer programs and partnerships in more than 50 countries. We are working to get cancer included in global health agendas, and will keep up that effort through global health programs that seek innovative solutions and the support of country leaders.
Komen alone has already invested millions in international research and community programs, launching education and treatment initiatives in Africa, the Middle East, Latin America and Central Europe. Komen employees and volunteers are on the ground in those regions of the world, sharing what we’ve learned about advocacy, education and awareness, and helping to develop “in country” programs that local organizations can implement to break through stigma, shame and lack of awareness about this disease. We will meet again Feb. 8 in Washington, D.C., with members of the global diplomatic community to enlist their support, part of our continuing effort to engage and activate country leaders, First Ladies and diplomats who can make a difference.
As we seek the world’s commitment, we are also hard at work looking for innovation in the way we educate and screen women in low-resource settings. Last year, we committed to finding cost-effective and sensitive screening technologies, and proposed partnerships to introduce screening and education to existing platforms in low-resource countries; that is, adding breast cancer education and screening to programs already in place for other diseases.
We do this because the need is real and growing. I have held the hands of women in poor countries, dying of breast cancer, many without even the most basic of palliative care. They ask me if their cancers are contagious. They worry for the futures of their daughters, fearful of the shame and stigma that their cancer has brought to their families.
We must move for these women and for future generations. We must move now. And we must move together.
No longer can organizations work in isolation, concerned about ownership over a program or disease. Collaboration and integration is the key to addressing the increasing burden of non-communicable diseases, including cancer, on communities worldwide.
I urge all who have been affected by this disease (and even those who haven’t) to sign the World Cancer Day Declaration and take these first steps to defeating one of mankind’s oldest scourges.
Click the image below to sign the World Cancer Day Declaration.
A big focus for Susan G. Komen for the Cure is innovation and collaboration in cancer research, and so I was very pleased this week to represent Komen before the President’s Cancer Panel – the three-member panel that reports to the president about the progress and effectiveness of the nation’s cancer programs. The President’s Cancer Panel holds meetings four times a year – this meeting was about the future of cancer research.
We focused our testimony on the need to answer the really difficult questions that still plague us in cancer research. In breast cancer, these include why some cancers spread aggressively and others don’t; how best to treat and attack aggressive and metastatic cancers; why cancer seems to be more prevalent or deadly in some groups of people than others, and, of course, the best strategies for preventing cancer all together. These are the questions we’re attempting to answer in Komen’s research program ($610 million invested in research to date),
We’re acutely aware, however, that no one agency, non-profit or research institution can come to these answers all by itself – there’s a lot that we can learn from each other, and truth is, we get better and more creative solutions when we find ways to share the vast knowledge that resides in the world’s laboratories and clinics.
Along these lines, we formalized this collaborative approach at Komen in 2008 with our Promise Grants program. Promise Grants are five-year, multi-million dollar grants aimed at getting to answers — urgently — for the toughest issues in breast cancer. These grants are just part of our research portfolio, and they’re unique in that they require collaboration between researchers, practitioners, advocates and others — sometimes within one institution, and sometimes across several institutions.
We currently have 14 Promise Grants looking into treatments for aggressive cancers and prevention strategies. We’re excited that seven of these are already going to clinical trials, just two-and-a-half years into our program. We expect that within the term of these grants we’ll see 16 clinical trials result.
We’ve also developed meaningful partnerships with institutions and research organizations, like the Translational Breast Cancer Research Consortium, the Susan G. Komen for the Cure Tissue Bank with Indiana University, the Institute of Medicine, the American Society of Clinical Oncology and the American Association for Cancer Research.
We do this because if we’ve learned nothing else in 30 years, it’s that cancer is extraordinarily complex. We’ve made a lot of progress in some areas, but there’s a lot more to do. It requires the cancer community to come together to address the issues, especially as we learn more about the genetic basics of cancer, and how new statistical models and data can help in cancer screening, prevention and care. Sharing information and working together can help us get to the answers more quickly.
I’d like to thank the President’s Cancer Panel for the opportunity to share Komen’s views today – this was especially meaningful because our founder and CEO, Nancy G. Brinker, was a member of this panel in the early 1990s. I invite you to learn more about Komen’s research programs here.
Guest post from Susan G. Komen for the Cure Manager of Community Health, Catherine Oliveros, DrPH
We find ourselves in Sao Paulo, Brazil enjoying its warm weather, familiarizing ourselves with its mountainous streets and learning that Sao Paulo is known, well, for…its pizza. Some locals report that the Brazilians have improved on the Italian version – we have yet to find out.
The true mission of our trip to Sao Paulo, however, is not to weigh in on the pizza debate, but more importantly to observe the pilot of Komen’s Community Educators Program (CEP), a new curriculum being launched as part of the Susan G. Komen for the Cure® Global Initiative for Breast Cancer Awareness.
This is exciting work, where we share what we’ve learned about how effective breast cancer education programs can lead to behavior change in communities with advocacy groups and health professionals “in country.” We’re working together to establish education programs that will lead to better breast cancer outcomes in Brazil. It was terrific meeting and working this week with a great group of individuals from Albert Einstein Hospital in Brazil. We had three days of training, led by the Brazil country team, Luciana Holtz de Camargo Barros and Maria Theresa Veit.
Our Community Educators Program builds on previous work that we have done in Brazil and 6 other countries through the Course for the Cure™ program.
About 45,000 women in Brazil were diagnosed with breast cancer in 2008 – it is the most prevalent cancer among women there. All of us are working to “downstage” the disease in Brazil, that is, get to a place where women arrive for medical treatment at the very earliest stages of breast cancer, when it is easier to treat.
I love being able to meet women and men who are as passionate about ending this disease as I am, no matter where they live and work. I’d like to thank our hosts in Brazil for a great and meaningful three days of training, and for a partnership that will be so meaningful. To learn more about our global work, visit http://www.globalkomen.org .
This weekend in Palm Beach, Florida, Komen kicks off the 2011 Susan G. Komen Race for the Cure series with the 20th anniversary of the South Florida Susan G. Komen Race for the Cure. There are now more than 1 million people running in more than 140 Komen races in countries all around the world – a huge jump from the 800 brave souls who first gathered in Dallas for the first Susan G. Komen Race for the Cure in 1982.
Some run to win, others to remember or celebrate a friend or loved one who is surviving a breast cancer diagnosis. They raise funds for research and the Komen programs that serve millions of women every day.
The Komen Race for the Cure series is open to everyone– young, old, rich, poor, and the famous. Among the famous? Hoda Kotb, NBC network host, who is a breast cancer survivor and honorary chair of the Palm Beach race.
Hoda talks here with Kelley Dunn of Channel 5 in Palm Beach about her own experience with breast cancer, what that first Race as a breast cancer survivor meant to her – and why the movement matters.
If you’ve had reconstructive surgery or are thinking about it, take note.
Yesterday, the FDA announced a possible link between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma (ALCL). While ALCL is extremely rare, the FDA believes women with breast implants may have a very small but increased risk of developing this disease in the scar capsule adjacent to the implant.
The disease is diagnosed in only 3 of 100 million women in the United States without breast implants and the FDA is aware of about 60 cases of ALCL worldwide in women with breast implants, which is small compared to the estimated 5 to 10 million women who have implants worldwide. The FDA is asking health care providers to be vigilant in considering ALCL and reporting confirmed cases to the FDA for further study. Additionally, the FDA does not recommend that women without symptoms consider removal of their implants, nor do they suggest any change in routine medical care or follow-up.
We encourage you to know your body and what is normal for you. Report any changes to your breast to your oncologist or plastic surgeon and if you’re considering the procedure, talk to your surgeon about the risks and benefits.